Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MB02 (Bevacizumab Biosimilar) vs Avastin in Healthy Japanese Males
NCT04238650Phase 1Completed
- Sponsor
- mAbxience
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab MB02 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 3 more (2 arms), sponsored by mAbxience. Primary endpoint: Area Under the Serum Concentration-time Curve From Time Zero to Infinity at Day 70. Started Aug 2019; status: completed.
02
Drugs
bevacizumab MB02
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04238650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238650.